Tyler Terry, NP
Pain Medicine · Greensboro, NCNPI 1467012054
Payments from drug & device makers
Across 238 payments — averaging $19.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Collegium Pharmaceutical, Inc.$568
- Lilly USA, LLC$445
- Pfizer$307
- Novo Nordisk$267
- Forte Bio-pharma LLC$225
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,606100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 58 | $1,096 |
| Collegium Pharmaceutical, Inc. | 31 | $568 |
| Lilly USA, LLC | 19 | $445 |
| Pfizer | 16 | $307 |
| Novo Nordisk | 19 | $267 |
| Forte Bio-pharma LLC | 9 | $225 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $184 |
| Mylan Specialty L.p. | 3 | $144 |
| Indivior Inc. | 8 | $142 |
| Virtus Pharmaceuticals LLC | 7 | $133 |
| AstraZeneca | 6 | $107 |
| Biohaven Pharmaceuticals, Inc. | 4 | $74 |
| Idorsia Pharmaceuticals US Inc | 4 | $72 |
| Otsuka America Pharmaceutical, Inc. | 3 | $70 |
| Amgen | 5 | $66 |
| Dexcom, Inc. | 2 | $64 |
| Exact Sciences | 3 | $51 |
| Lundbeck LLC | 2 | $47 |
| Bayer | 3 | $45 |
| Kowa Pharmaceuticals America, Inc. | 3 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $44 |
| GSK | 2 | $32 |
| Viatris Specialty LLC | 1 | $32 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $32 |
| Baxter Healthcare | 1 | $31 |
| Corcept Therapeutics | 1 | $30 |
| Merck | 2 | $26 |
| Averitas Pharma Inc. | 1 | $25 |
| Antares Pharma, Inc. | 1 | $24 |
| Scilex Pharmaceuticals Inc. | 1 | $24 |
| Medtronic | 1 | $24 |
| Eisai Inc. | 1 | $21 |
| GRT US Holding, Inc. | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Tonix Medicines, Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| ANI Pharmaceuticals, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,606 in reported general payments places this provider in the 50th percentile of 182 pain medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 698 | $177,421 |
| MounjaroTirzepatide | 88 | $105,685 |
| OzempicSemaglutide | 87 | $88,528 |
| FarxigaDapagliflozin Propanediol | 38 | $50,729 |
| Xtampza ErOxycodone Myristate | 71 | $38,801 |
| VraylarCariprazine Hcl | 19 | $28,366 |
| LinzessLinaclotide | 29 | $26,809 |
| BelbucaBuprenorphine Hcl | 27 | $25,992 |
| TrulicityDulaglutide | 23 | $22,840 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 34 | $21,135 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 164 | $21,026 |
| XareltoRivaroxaban | 17 | $18,793 |
| Oxycodone Hcl | 687 | $15,228 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 413 | $13,628 |
| EliquisApixaban | 13 | $12,035 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $445 | $128,525111 claims |
| Novo NordiskOzempic | $267 | $88,52887 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca, Nucynta Er | $568 | $72,818110 claims |
| AstraZenecaFarxiga, Symbicort | $107 | $55,65757 claims |
| AbbVieVraylar, Linzess | $1,096 | $55,17548 claims |
| Indivior Inc.Suboxone | $142 | $21,13534 claims |
| PfizerEliquis, Lyrica | $307 | $19,33825 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $24 | $1,28412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 182 pain medicine providers in North Carolina.
Other pain medicine in Greensboro
- Enrico JonesGreensboro$38K
- Kyle SebastianGreensboro$14K
- Dave EichmanGreensboro$12K
- Yun SunGreensboro$9K
- Leonardo KapuralWinston Salem$4.1M
- James NorthWinston Salem$3.7M
- Richard RauckWinston Salem$1.7M
- Christopher GilmoreWinston Salem$1.3M
- Binit ShahHuntersville$863K
- Jeffrey PeacockWinston Salem$553K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.